The Startup Drugmaker's Post-Helsinn Survival Guide

By Dani Kass (January 25, 2019, 9:38 PM EST) -- The U.S. Supreme Court dashed the hopes of smaller pharmaceutical and biotech companies with its recent ruling that businesses can't sell unpatented inventions to other companies without risking losing their future patent rights, possibly cutting off years of market exclusivity.

While the court's Jan. 22 ruling in Helsinn v. Teva will apply to all drug companies, startups and other small businesses are likely to feel it more acutely, given that they don't have a wealth of in-house services at their disposal. Experts say that as long as these companies are diligent, the ruling shouldn't throw a wrench into their business....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!